CADTH Health Technology Review

Antiviral Prophylaxis With Tenofovir for Patients With History of Hepatitis B Receiving Oncology Drug Treatment

Rapid Review

CADTH

Table of Contents

List of Tables

List of Figures

Abbreviations

ALT   alanine aminotransferase

Anti-HBc   HBV core antibody

Anti-HBe   HBV envelop antibody

Anti-HBs   HBV surface antibody

DNA   deoxyribose nucleic acid

ETV   entecavir

eGFR   estimated glomerular filtration rate

HBeAg   HBV envelope antigen

HBsAg   HBV surface antigen

HBV   hepatitis B virus

Ig   immunoglobulin

ITT   intention-to-treat

RCT   randomized controlled trial

TAF   tenofovir alafenamide

TDF   tenofovir disoproxil fumarate

Key Messages

- One randomized control trial and 2 retrospective cohort studies found no significant differences between tenofovir and entecavir in the prophylaxis of hepatitis B virus reactivation in patients who were hepatitis B surface antigen positive and/or hepatitis B core antibody positive receiving chemotherapy or immunosuppressive therapy. There were no significant differences between these 2 drugs regarding renal function and other side effects.
- One randomized controlled trial found no patients in the tenofovir prophylaxis group had HBV reactivation compared to 10.7% in the observational group. However, the difference did not reach the level of statistical significance, probably owing to a small sample size. There were no significant differences between groups in terms of renal function, liver function, and other side effects.
- All 8 included guidelines strongly recommend the use of tenofovir or entecavir as antiviral prophylaxis in all patients with high risk of hepatitis B virus reactivation (hepatitis B surface antigen positive and/or hepatitis B core antibody positive) during chemotherapy or immunosuppressive therapy.

Context and Policy Issues

Hepatitis B virus (HBV) infection is a vaccine-preventable viral infection mainly affecting the liver that can cause both acute and chronic illness, causing permanent liver damage and liver cancer if left untreated.[1] In 2018, there were a total of 4,783 cases in Canada, of which 189 cases were acute (0.52 per 100,000 population), 3,483 cases were chronic (10.6 per 100,000 population), and 751 cases were unspecified (2.1 per 100,000 population).[1] Between 2009 and 2018, the overall rate of chronic HBV infection decreased from 13.4 to 10.6 per 100,000 population.[1] There is no cure for the disease; however, it can be successfully treated with antiviral medications to slow down the disease progression and improve survival.[1]

Once the cells get infected by HBV, the covalently closed circular deoxyribose nucleic acid (DNA) remains permanently inside the host cells and serves as a template for future viral replication.[2] Diagnosis and distinguishing between acute and chronic infections are made by serological testing to detect HBV surface antigen (HBsAg), HBV envelope antigen (HBeAg), HBV surface antibody (anti-HBs), HBV core antibody (anti-HBc), HBV envelop antibody (anti-HBe), and HBV-DNA. Acute HBV infection is defined when a person without a history HBV infection is first infected and loses the HBsAg within 6 months after the onset. Patients are diagnosed as having a chronic HBV infection if the HBsAg persist 6 months after onset of acute hepatitis.[2] Patients whose HBV infections resolve within 6 months have undetected HBsAg and HBV-DNA but become anti-HBs-positive and anti-HBc-positive. People with immunity through vaccination have anti-HBs-positive, HBsAg-negative, anti-HBc-negative, and undetectable HBV-DNA.[2]

Cancer patients with chronic HBV (HBsAg-positive) or those with resolved or past HBV infection are at high risk for HBV reactivation during chemotherapy or immunosuppressive therapy.[3,4] HBV reactivation is defined as an increase of serum HBV-DNA greater than 1 $\log_{10}$ IU/mL or a 10-fold increase from baseline, or a new HBV-DNA detection.[5-7] When HBV reactivation presents with an increase in alanine aminotransferase (ALT) levels, there is an

increased risk of mortality due to liver failure, interruption of cancer therapy and lower overall survival.[4,8]

There are 2 approaches of treatment of HBV reactivation, either by offering antiviral prophylaxis to all patients considered at moderate or high risk before starting chemotherapy or immunosuppressive therapy, or by regular monitoring of HBsAg, HBV DNA, and ALT, and starting antiviral therapy when HBV-DNA and/or ALT levels increase (so called pre-emptive approach).[9] Antiviral prophylactic treatment has been found to be more effective in preventing HBV reactivation than the pre-emptive approach.[10-12] A number of nucleoside and nucleotide analogue drugs, including lamivudine, telbivudine, clevudine, adefovir, entecavir, and tenofovir have been developed to block the HBV-DNA polymerase enzyme activity, thus inhibiting HBV replication.[13] Of those drugs, entecavir and tenofovir have high antiviral potency and high genetic barrier making it less likely to develop drug-resistant HBV mutants during prolonged treatment.[13]

This report aims to summarize the clinical effectiveness of tenofovir for antiviral prophylaxis in patients with a history of HBV infection who are receiving oncology drug treatment. Additionally, this report aims to summarize the recommendations from evidence-based guidelines regarding the use tenofovir as antiviral prophylaxis for that patient population.

Research Questions

1. What is the clinical effectiveness of antiviral prophylaxis with tenofovir for patients with history of hepatitis B who are receiving oncology drug treatment?

2. What are the evidence-based guidelines for antiviral prophylaxis with tenofovir for patients with history of hepatitis B who are receiving oncology drug treatment?

Methods

Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, the Cochrane Database of Systematic Reviews, the International HTA Database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy comprised controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were hepatitis B and tenofovir and cancer or cancer drugs. A CADTH-developed search filter was applied to limit retrieval to guidelines for a secondary search of the concepts hepatitis b and cancer or cancer drugs. The search was completed on July 19, 2022 and limited to English-language documents published since January 1, 2017.

Selection Criteria and Methods

One reviewer screened citations and selected studies. In the first level of screening, titles and abstracts were reviewed and potentially relevant articles were retrieved and assessed for

inclusion. The final selection of full-text articles was based on the inclusion criteria presented in Table 1.

Exclusion Criteria

Articles were excluded if they did not meet the selection criteria outlined in Table 1, they were duplicate publications, they were published before 2017. Guidelines with unclear methodology were also excluded.

Critical Appraisal of Individual Studies

The included publications were critically appraised by 1 reviewer using the following tools as a guide: the Downs and Black checklist[14] for randomized and non-randomized studies, and the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument[15] for guidelines. Summary scores were not calculated for the included studies; rather, the strengths and limitations of each included publication were described narratively.

Summary of Evidence

Quantity of Research Available

A total of 465 citations were identified in the literature search. Following screening of titles and abstracts, 431 citations were excluded and 34 potentially relevant reports from the electronic search were retrieved for full-text review. Eleven potentially relevant publications were retrieved from the grey literature search for full-text review. Of these 45 potentially relevant articles, 33 publications were excluded for various reasons, and 12 publications met the inclusion criteria and were included in this report. These comprised 2 randomized controlled trials (RCTs), 2 non-randomized studies, and 8 evidence-based guidelines. Appendix 1 presents the PRISMA[16] flow chart of the study selection.

Additional references of potential interest are provided in Appendix 5.

Table 1: Selection Criteria

Criteria	Description
Population	Q1 and Q2: Patients with history of hepatitis B (i.e., hepatitis B core antibody positive, hepatitis B antigen positive) who are receiving oncology drug treatment
Intervention	Q1 and Q2: Tenofovir
Comparator	Q1: Other antiviral drugs (i.e., lamivudine, adefovir, telbivudine, entecavir), placebo
	Q2: NA
Outcomes	Q1: Clinical effectiveness i.e., clinical benefits (e.g., prevention of hepatitis B reactivation, hospitalization, and death) and harms (e.g., adverse events, disruption of oncology drug treatment)
	Q2: Evidence-based recommendations addressing best clinical practice
Study designs	Q1: Health technology assessments, systematic reviews, randomized-controlled trials, non-randomized studies
	Q2: Evidence-based guidelines

NA = not applicable.

Summary of Study Characteristics

Additional details regarding the characteristics of included clinical studies (Table 2) and guidelines (Table 3) are provided in Appendix 2.

Study Design

The 4 included primary clinical studies comprised 2 RCTs[17,18] and 2 retrospective cohort studies.[19,20] The RCTs were published in 2021[17] and 2017,[18] while the 2 retrospective cohort studies were published in 2021[19] and 2018.[20] One RCT[17] was parallel and from a single centre (a university). Blinding status in this RCT[17] was not reported. The other RCT[18] was multi-centre (17 hospitals), phase IV, open-label, and parallel. Both RCTs reported that sample size calculation for primary outcomes was performed. One RCT[18] analyzed the data using the intention-to-treat (ITT) approach, while the other[17] analyzed the data as per protocol. The 2 retrospective cohort studies[19,20] did not perform sample size calculation and did not identify and adjust for confounding variables in the analyses.

All the included guidelines[21-28] provide recommendations for the diagnosis, prophylaxis, and/or management of HBV infection. All included guidelines were not explicit about evidence collection, selection, and synthesis. Six guidelines.[21,23-25,27,28] graded the level of evidence and the strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.[21,23-25,27,28] Two guidelines[22,26] graded the level of evidence and the strength of recommendations using predefined criteria.

Country of Origin

The primary clinical studies were conducted by authors from Turkey,[17] Spain,[18] Japan,[19] and Taiwan.[20]

The guidelines were conducted by authors from Australia,[21,24] Germany,[22] Brazil,[23] India,[25] US,[26] Canada,[27] and Italy.[28]

Patient Population

One RCT[17] involved patients undergoing immunosuppressive treatments for onco-hematologic diseases, who had HBsAg and/or anti-HBc positivity, and were susceptible HBV reactivation. The other RCT[18] involved patients with hematological malignancy receiving rituximab-based regimens either as monotherapy or in combination with chemotherapy. One retrospective cohort study[19] involved patients undergoing chemotherapy or immunosuppressive therapy for cancer who had previous HBV infection or were HBV carriers. The other retrospective cohort study[20] involved HBsAg-positive cancer patients undergoing chemotherapy.

The target population in the included guidelines[21-28] were patients with HBV infection including those with high risk of HBV reactivation during chemotherapy or immunosuppressive treatments for hematological and solid tumour malignancies.

Interventions and Comparators

Two clinical studies[17,20] compared tenofovir disoproxil fumarate (TDF) (245 or 300 mg/day) with entecavir (ETV) (0.5 mg/day), 1 study[19] compared tenofovir alafenamide (TAF) (dosage not reported) with ETV (dosage not reported), and 1 study[18] compared TDF (300 mg/day) with observation. The drugs were used as antiviral prophylaxis with a treatment period ranging from 24 weeks to 18 months.

All the included guidelines[21-28] considered antiviral prophylaxis drugs, such as ETV, TDF or TAF, for patients undergoing chemotherapy or immunosuppressive treatments.

Outcomes

The outcomes considered in the included primary clinical studies were HBV reactivation including HBV reactivation rates[17,18,20] and rates of undetectable HBV-DNA levels.[17,19] The treatment-related side effects were kidney function,[18-20] liver function,[18] and others.[17]

All the included guidelines[21-28] considered efficacy and safety outcomes related to the intervention and practice considered.

Summary of Critical Appraisal

Additional details regarding the strengths and limitations of included primary clinical studies (Table 4) and guidelines (Table 5) are provided in Appendix 3.

With respect to reporting, the 2 RCTs[17,18] and 2 retrospective cohort studies[19,20] clearly described the study objectives, interventions of interest, main outcome measures, and the main findings. The baseline patient characteristics were described in all studies. All studies reported treatment-related adverse events. Both RCTs[17,18] did not describe the characteristics of patients lost to follow-up. One RCT[18] used the ITT approach in the data analyses to account for patients lost to follow-up. Not accounting for patients lost to follow-up in the analyses may increase potential risk of attrition bias. In both retrospective cohort studies,[19,20] there were no apparent group differences in most reported demographics of the included patients. However, there may exist confounding variables in both studies that were not identified and adjusted, and their impact on the findings is unknown. Actual P values (i.e., P values) and measures of random variability (e.g., confidence interval, standard deviation, or interquartile range) in the data for the main outcomes were reported in all included studies.[17-20] Regarding external validity, it was unclear if the patients represent the entire population from which they were recruited in all included studies. For internal validity, 1 RCT[17] did not report whether blinding to patients, investigators and outcome assessors was applied. The other RCT[18] was an open-label trial. Non-blinding of patients and personnel may lead to performance bias, and non-blinding of outcome assessors may result in detection bias. Both RCTs[17,18] did not report the methods of allocation concealment. Not performing allocation concealment may result in risk of selection bias. Sample size calculation was performed in both RCTs,[17,18] but in 1 RCT,[18] the calculated sample size was not reached, suggesting the study did not have the anticipated power to detect a clinically important effect. Both retrospective cohort studies[19,20] may be prone to high risk of bias for selection, performance, and detection due to the nature of the observational study design. Additionally, confounding variables that could have significant impact on the findings were not identified and adjusted for in the analyses in these studies.[19,20] Appropriate statistical tests were used to assess the main outcomes, and reliable and validated outcome measures were used in all included studies.[17-20] Overall, all the included clinical studies[17-20] were of low methodological quality.

All included guidelines[21-28] were explicit in terms of scope and purpose (i.e., objectives, health questions and populations), and had clear presentation (i.e., specific, unambiguous, and easy to find key recommendations, with options for managing the different conditions or health issues). In terms of stakeholder involvement, all included guidelines[21-28] clearly defined target users and the development groups. However, it was unclear if the views and preferences of the patients were sought in all guidelines except the Australian guideline.[21] All the included guidelines[21-28] did not clearly report on evidence collection, criteria for selection and on

evidence synthesis. However, there were explicit link between recommendations and the supporting evidence, and methods of formulating the recommendations in all guidelines.[21-28] Also, all guidelines[21-28] considered health benefits and risks of side effects in formulating the recommendations. They included procedures for updating the guidelines and were externally peer-reviewed before publication. Two guidelines[22,26] used the predefined criteria while 6 guidelines[21,23-25,27,28] used the GRADE methodology to assess the level of evidence and grade their recommendations. It is unknown if the criteria had been validated for assessing the clinical guidelines. For applicability, it was unclear in terms of facilitators and barriers to application, advice and/or tools on how the recommendations can be put into practice, resource implications, and monitoring or auditing criteria in all included guidelines, except the Australian guideline by Doyle at al. (2019).[24] For editorial independence, all guidelines[21-28] reported competing interests of guideline development group members, but did not report if the views of the funding body had any influence on the content of the guidelines. Overall, all the included guidelines were of moderate methodological quality.

Summary of Findings

Appendix 4 presents the main study findings of the primary clinical studies[17-20] (Table 6 and Table 7) and the summary of guideline recommendations[21-28] (Table 8).

Clinical Effectiveness of Antiviral Prophylaxis With Tenofovir for Patients With History of Hepatitis B Who Are Receiving Oncology Drug Treatment

One RCT[17] and 1 retrospective cohort study[20] compared TDF with ETV, 1 retrospective cohort study[19] compared TAF with ETV, and 1 RCT[18] compared TDF with observation.

HBV Reactivation

Tenofovir Disoproxil Fumarate Versus Entecavir

The RCT by Toka et al. (2021)[17] found that, in patients who were HBsAg and/or anti-HBc IgG positive and scheduled to receive immunosuppressive treatments for oncologic and hematologic diseases, all patients became HBV-DNA negative within 12 months of starting antiviral prophylaxis with TDF or ETV. Antiviral prophylaxis was given during immunosuppressive treatments. There was no significant difference in time to achieve DNA negativity in TDF group compared with ETV group (5.22 ± 3.02 months versus 5.40 ± 3.16 months; P = 0.84). There was no HBV reactivation in both groups, defined as at least 1 log increase in HBV-DNA from baseline levels or reappearance of HBV-DNA in individual who previously had an undetectable HBV-DNA. Patients were follow-up 1 year after completion of prophylaxis. During that the follow-up period, 14.3% of patients in the TDF group and 10.8% of patients in ETV group had HBV reactivation. A measure of statistical significance, such as P value, was not reported.

The retrospective cohort study by Lee et al. (2018)[20] found that, for a median of 14 months treatment with TDF or ETV as antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy, 95.5% and 85.7% of patients in the TDF and ETV groups, respectively, achieved undetectable HBV-DNA; P = 0.056. HBV reactivation rates, defined as an increase in HBV DNA levels 10-fold or more compared with the previous nadir levels, were 0.9% (1 patient) in the TDF group and 0.9% (1 patient) in the ETV group; P = 1.00.

Tenofovir Alafenamide Versus Entecavir

The RCT by Inada et al. (2021)[19] found that, in patients receiving TAF or ETV as prophylaxis against or treatment for HBV reactivation, there was no significant difference between groups

in the reduction in serum HBV-DNA from baseline to week 24 (−3.04 ± 2.47 versus −2.83 ± 1.45; P = 0.857). At week 24, HBV-DNA was undetectable in serum of 90.9% of patients in the TAF group versus 78.8% of patients in the ETV group (78.8%); P = 0.681.

Tenofovir Disoproxil Fumarate Versus Observation

The RCT by Buti et al. (2017)[18] found that, in anti-HBc-positive patients with hematological malignancy receiving rituximab-based regimens either as monotherapy or as combination with chemotherapy, HBV reactivation (defined as HBsAg and/or HBV-DNA detection, or a confirmed ≥ 1 log IU/mL increase in HBV-DNA levels from baseline) was 0% in the TDF group compared to 10.7% in the observation groups after 18 months of treatment; P = 0.091. The results were similar in both intention-to-treat analysis and per protocol analysis.

Side Effects − Renal Function

Tenofovir Disoproxil Fumarate Versus Entecavir

The retrospective cohort study by Lee et al. (2018)[20] found no significant difference in risk of renal events in HBsAg-positive cancer patients receiving TDF or ETV as antiviral prophylaxis during chemotherapy. Parameters investigated included incidence of acute kidney injury (33% versus 38.9%; P = 0.441), incidence of sustained kidney injury (11.3% versus 11.5%; P = 1.00), decrease in the estimated glomerular filtration rate (eGFR) of at least 20% (59.4% versus 60.2%); P = 1.00), decrease in eGFR ≥ 50% (9.4% versus 18.6%; P = 0.081), eGFR < 60 mL/min (27.4% versus 38.9%; P = 0.094), eGFR of less than 30 mL/min (3.8% versus 11.5%; P = 0.060), dose of TDF or ETV adjustment (12.3% versus 23.9%; P = 0.040), and serum phosphorous of less than 2 mg/dL (4.7% versus 4.4%; P = 1.000).

Tenofovir Alafenamide Versus Entecavir

The retrospective cohort study by Inada et al. (2021)[19] found no significant difference in the decrease in the eGFR between the TAF group (−3.67 ± 13.19 mL/min/1.73 m^2) and the ETV group (−0.62 ± 11.22 mL/min/1.73 m^2); P = 0.291 at week 24.

Tenofovir Disoproxil Fumarate Versus Observation

The RCT by Buti et al. (2017)[18] reported that the between-group analyses showed no significant differences between TDF and observation in renal function parameters, including serum creatinine, GFR, creatinine clearance, and serum phosphate at baseline and at month 18. The data for that comparison were not reported.

Side Effects − Liver Function

Tenofovir Disoproxil Fumarate Versus Observation

The RCT by Buti et al. (2017)[18] reported that the between-group analyses showed no significant differences between TDF and observation in liver function parameters, including alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, bilirubin, albumin, alkaline phosphatase, and platelets at baseline and at month 18. The data for that comparison were not reported.

Side Effects − Others

Tenofovir Disoproxil Fumarate Versus Entecavir

The RCT by Toka et al. (2021)[17] found no significant difference between TDF and ETV groups in the proportion of patients who had at least 1 side effects that did not require treatment disruption (23.3% versus 16.7%; P = 0.77). Examples of the side effects were sleep disturbances, headache, hematuria, abdominal pain, myalgia, nausea, weakness, and

itching or rash on skin. One patient in the TDF group had to switch to ETV due to severe itchy, maculopapular, rash-like lesions. [17]About 35% of patients in both groups died due to primary disease during prophylaxis, but the authors did not investigate whether antiviral prophylaxis with EVT or TDF played any role in the cause of deaths.

Guidelines Regarding the Use of Antiviral Prophylaxis With Tenofovir for Patients with History of Hepatitis B Who Are Receiving Oncology Drug Treatment

The Australian guideline[21] published in 2022 strongly recommends entecavir or tenofovir treatment for HBsAg positive patients receiving cancer chemotherapy. The guideline also strongly recommends entecavir or tenofovir treatment for HBsAg-negative and anti-HBc positive patients who are being treated with drugs that are associated with a high risk of HBV reactivation.

Another Australian guideline[24] published in 2019 also strongly recommends the use of entecavir or tenofovir as antiviral prophylaxis as soon as possible in all children or adult HBsAg positive patients with hematological or solid tumour malignancy undergoing higher risk cancer therapy (hematopoietic stem-cell transplantation [HSCT]; B-cell depleting, B-cell active or anti-CD20 drugs; acute leukemia and high-grade lymphoma therapy).

The German guideline[22] published in 2021 strongly recommends the use of either tenofovir or entecavir in patients at high risk for HBV reactivation such as those with HBsAg- and/or anti-HBc positive undergoing high-dose chemotherapy, autologous stem-cell transplantation, steroid medication, and anti-CD20-antibodies treatment.

The Brazilian guideline[23] published in 2020 strongly recommends that entecavir or tenofovir should be used as antiviral prophylaxis in all patients with high risk of HBV reactivation (i.e., HBsAg-positive and anti-HBc-positive, or HBsAg-negative and anti-HBc-positive) undergoing chemotherapy or immunosuppressive therapy. Treatment with entecavir or tenofovir should be maintained for 6 months, or 12 to 18 months in case of rituximab, after discontinuation of chemotherapy or immunosuppressive therapy.

The Indian guideline[25] published in 2018 strongly recommends that entecavir or tenofovir should be used as antiviral prophylaxis to prevent HBV reactivation in adult patients undergoing chemotherapy or immunosuppressive therapy. Entecavir should be used for children 2 years and older; whereas entecavir or tenofovir can be used for children 12 years and older. The guideline also strongly recommends that antiviral prophylaxis therapy with entecavir or tenofovir should be started immediately in HBsAg-positive or HBV-DNA positive patients. In anti-HBc-positive, but HBsAg and HBV DNA negative patients, antiviral prophylaxis against HBV reactivation can be initiated in those at high-risk groups such as patients with lymphoma under a rituximab-containing regimen or those undergoing HSCT. The guideline strongly recommends that antiviral prophylaxis treatment should be continued for at least 12 months after discontinuation of chemotherapy or immunosuppressive therapy, or 18 months for rituximab-based regimens and HSCT.

The American guideline[26] published in 2018 moderately recommends entecavir or tenofovir be used as antiviral prophylaxis in patients with high risk of HBV reactivation undergoing cancer therapy.

The Canadian guideline[27] published in 2018 strongly recommends that patients undergoing immunosuppressive therapy or chemotherapy with high risk of HBV reactivation, such as

those with HBsAg-positive, should undergo either monitoring or prophylactic therapy with entecavir or tenofovir. Monitoring or prophylactic therapy should also be applied to HBsAg-negative, anti-HBc-positive patients. The guideline strongly recommends that monitoring or prophylactic therapy should be continued for at least 12 months after completion of immunosuppressive therapy, or longer in patients who received B-cell depleting therapies.

The Italian guideline[28] published in 2017 strongly recommends that antiviral prophylaxis drugs such as entecavir or tenofovir should be used to treat HBsAg-positive patients undergoing chemotherapy. The guideline also strongly recommends antiviral prophylaxis be initiated at least 1 week before or at the same time when starting chemotherapy. Antiviral prophylaxis should be administered during chemotherapy and should be continued for at least 12 to 24 months after completion of chemotherapy. The guideline also recommends subsequent monitoring for late HBV reactivation after the termination of the antiviral prophylaxis.

Limitations

The included clinical studies had several limitations. Both RCTs[17,18] were limited in terms of sample size. Although sample size calculation was performed in the RCT by Toka et al. (2021),[17] about 35% of patients died during prophylaxis therapy due to primary disease, leading to uncertainty about the study's power to detect a significant difference between groups in the analysis. In the RCT by Buti et al. (2017),[18] the calculated sample size was not reached; therefore, it was unclear whether the observed trend of numerically greater effectiveness of TDF than close monitoring in reducing HBV reactivation rate could reach statistical significance if the study had included the pre-estimated sample size. HBV genotype was not evaluated or reported in both RCTs.[17,18] The non-randomized design of the 2 retrospective cohort studies[19,20] indicate that they have risk of selection bias. The retrospective cohort study by Lee et al. (2018)[20] enrolled patients with selected baseline characteristics, such as those with serum creatinine less than 1.2 mg/dL and those without liver cirrhosis, thus limiting the generalizability of the findings. The follow-up period in the retrospective cohort study by Inada et al. (2021)[19] may not be long enough (i.e., 24 weeks) to examine the long-term safety and effects of TAF or ETV. The course of monitoring after TDF/TAF or ETV discontinuation was not described in any of the included studies.[17-20]

All the included guidelines[21-28] did not clearly report the methods of collection, selection, and synthesis of the evidence.

Conclusions and Implications for Decision- or Policy-Making

This report identified 2 RCTs,[17,18] 2 retrospective cohort studies,[19,20] and 8 guidelines.[21-28] The identified primary clinical studies provided evidence for the efficacy and safety of tenofovir compared with entecavir,[17,19,20] or tenofovir compared with observation,[18] as antiviral prophylaxis against HBV reactivation in patients with history of HBV infection undergoing oncology drug treatment.

Efficacy against HBV reactivation was similar between tenofovir and entecavir, with no significant difference between the 2 for antiviral prophylaxis in patients who were HBsAg and/or anti-HBc positive receiving chemotherapy or immunosuppressive therapy. There was also no significant difference in renal function or other side effects between tenofovir and entecavir for antiviral prophylaxis. HBV reactivation did not occur in patients given tenofovir prophylaxis (0%) compared with observation group (10.7%), but the difference was not statistically significant. In terms of safety, patients in tenofovir group showed no significant differences in renal function and liver function parameters compared with those in the observation group.

All included guidelines[21-28] strongly recommend the use of tenofovir or entecavir as antiviral prophylaxis in all patients with high risk of HBV reactivation (HBsAg-positive and/or anti-HBc-positive) during the course of chemotherapy or immunosuppressive therapy. Some guidelines[23,25,28] recommend that antiviral prophylaxis with tenofovir or entecavir continues for 6 months to 18 months after completion of chemotherapy or immunosuppressive therapy. Thus, entecavir and tenofovir are favourable drugs in the prophylaxis and treatment of HBV reactivation.[29]

Given the unanimous recommendations of the included guidelines and the evidence from the included clinical studies, tenofovir and entecavir appear to be efficacious and safe as antiviral prophylaxis drugs to prevent HBV reactivation in patients undergoing chemotherapy or immunosuppressive therapy. The findings in this report are applicable to the Canadian context. One guideline[25] from India recommends using entecavir in children 2 years and older, and entecavir or tenofovir in adults or children 12 years and older. One Australian guideline[24] also recommends the use of entecavir or tenofovir in all children or adult HBsAg positive patients. However, the choice between tenofovir and entecavir for specific populations remains to be determined. Also, well-controlled trials with larger sample sizes and longer follow-up periods are needed.

References

1. Health Canada. Report on hepatitis B and C in Canada: 2018. 2021; https://www.canada.ca/en/public-health/services/publications/diseases-conditions/report-hepatitis-b-c-canada-2018.html. Accessed 2022 Aug 8.

2. Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. *JAMA.* 2018;319(17):1802-1813. PubMed

3. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. *Clin Gastroenterol Hepatol.* 2006;4(9):1076-1081. PubMed

4. Wang B, Mufti G, Agarwal K. Reactivation of hepatitis B virus infection in patients with hematologic disorders. *Haematologica.* 2019;104(3):435-443. PubMed

5. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? *Hepatology.* 2015;61(2):703-711. PubMed

6. Law MF, Ho R, Cheung CK, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. *World J Gastroenterol.* 2016;22(28):6484-6500. PubMed

7. Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. *Hepatology.* 2016;63(1):261-283. PubMed

8. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. *Gastroenterology.* 2015;148(1):221-244 e223. PubMed

9. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. *Gastroenterology.* 2017;152(6):1297-1309. PubMed

10. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. *J Clin Oncol.* 2013;31(22):2765-2772. PubMed

11. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. *Gastroenterology.* 2003;125(6):1742-1749. PubMed

12. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. *Hepatology.* 2008;47(3):844-853. PubMed

13. Kim SS, Cheong JY, Cho SW. Current nucleos(t)ide analogue therapy for chronic hepatitis B. *Gut Liver.* 2011;5(3):278-287. PubMed

14. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health.* 1998;52(6):377-384. PubMed

15. Agree Next Steps C. The AGREE II Instrument. [Hamilton, ON]: AGREE Enterprise; 2017: https://www.agreetrust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf. Accessed 2022 Aug 24.

16. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol.* 2009;62(10):e1-e34. PubMed

17. Toka B, Koksal AS, Eminler AT, Tozlu M, Uslan MI, Parlak E. Comparison of tenofovir disoproxil fumarate and entecavir in the prophylaxis of HBV reactivation. *Dig Dis Sci.* 2021;66(7):2417-2426. PubMed

18. Buti M, Manzano ML, Morillas RM, et al. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study. *PLoS One.* 2017;12(9):e0184550. PubMed

19. Inada K, Kaneko S, Kurosaki M, et al. Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. *JGH Open.* 2021;5(9):1085-1091. PubMed

20. Lee IC, Chao Y, Li CP, et al. Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy. *J Viral Hepatitis.* 2018;25(12):1599-1607. PubMed

21. Lubel JS, Strasser SI, Thompson AJ, et al. Australian consensus recommendations for the management of hepatitis B. *Med J Aust.* 2022;216(9):478-486. PubMed

22. Christopeit M, Schmidt-Hieber M, Sprute R, et al. Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Ann Hematol.* 2021;100(2):321-336. PubMed

23. Ferraz ML, Strauss E, Perez RM, et al. Brazilian Society of Hepatology and Brazilian Society of Infectious Diseases guidelines for the diagnosis and treatment of hepatitis B. *Braz J Infect Dis.* 2020;24(5):434-451. PubMed

24. Doyle J, Raggatt M, Slavin M, et al. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. *Med J Aust.* 2019;210(10):462-468. PubMed

25. Arora A, Anand AC, Kumar A, et al. INASL guidelines on management of hepatitis B virus infection in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids. *J Clin Exp Hepatol.* 2018;8(4):403-431. PubMed

26. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. *J Clin Oncol.* 2018;36(30):3043-3054. PubMed

27. Coffin CS, Fung SK, Alvarez F, et al. Management of hepatitis B virus infection: 2018 guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. *Can Liver J.* 2018;1(4):156-217. PubMed

28. Sarmati L, Andreoni M, Antonelli G, et al. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. *Clin Microbiol Infect.* 2017;23(12):935-940. PubMed

29. Tsai YF, Hsu CM, Hsiao HH. Management of hepatitis B virus reactivation in malignant lymphoma prior to immunosuppressive treatment. *J Pers Med.* 2021;11(4). PubMed

30. ASCO guidelines methodology manual. Alexandria (VA): American Society of Clinical Oncology; 2019: https://www.asco.org/sites/new-www.asco.org/files/content -files/practice-and-guidelines/documents/2019-Guidelines-Methodology-Manual.pdf. Accessed 2022 Jul 26.

Appendix 1: Selection of Included Studies

Figure 1: Selection of Included Studies

```
┌─────────────────────────────────────┐
│ 465 citations identified from        │
│ electronic literature search and     │
│ screened                             │
└─────────────────────────────────────┘
                  │
                  │────────────────────►  ┌──────────────────────┐
                  │                       │ 431 citations excluded│
                  │                       └──────────────────────┘
                  ▼
┌─────────────────────────────────────┐
│ 34 potentially relevant articles     │
│ retrieved for scrutiny (full text,   │
│ if available)                        │
└─────────────────────────────────────┘
                  ▲
┌───────────────────────────┐         │
│ 11 potentially relevant    │────────►│
│ reports retrieved from     │         │
│ other sources (grey        │         │
│ literature, handsearch)    │         │
└───────────────────────────┘         ▼
┌─────────────────────────────────────┐
│ 45 potentially relevant reports      │
└─────────────────────────────────────┘
                  │
                  │────────────────────►  ┌────────────────────────────────────┐
                  │                       │ 33 reports excluded:               │
                  │                       │ • Irrelevant intervention (6)      │
                  │                       │ • Guidelines with unclear          │
                  │                       │   methodology (2)                  │
                  │                       │ • Duplicate guidelines (2)         │
                  │                       │ • Others (e.g., review articles,   │
                  │                       │   editorials) (23)                 │
                  ▼                       └────────────────────────────────────┘
┌─────────────────────────────────────┐
│ 12 reports included in review        │
│ comprising 2 randomized controlled   │
│ trials, 2 retrospective cohort       │
│ studies, and 8 guidelines            │
└─────────────────────────────────────┘
```

Appendix 2: Characteristics of Included Publications

Note that this appendix has not been copy-edited.

Table 2: Characteristics of Included Primary Clinical Studies

Study citation, country, funding source	Study design	Population characteristics	Intervention and comparator(s)	Clinical outcomes, length of follow-up
Toka et al. (2021)[17] Turkey **Funding source:** The study was funded by the authors	Single-centre, parallel RCT Setting: University Sample size calculation: Yes ITT analysis: No	Patients who had HBsAg and/or anti-HBc positivity, susceptible HBV reactivation, and receiving IST for oncohematologic diseases. Mean age (SD), years: • TDF: 57.9 (11.2) • ETV: 58.5 (12.7); P = 0.69 % Male: • TDF: 52 • ETV: 55; P = 0.85 % HBsAg-positive: • TDF: 63.3 • ETV: 51.7; P = 0.27 % Isolated anti-HBc IgG-positive: • TDF: 36.7 • ETV: 48.3; P = 0.26 % HBeAg-positive: • TDF: 3.3 • ETV: 5; P = 1 % HBV-DNA-positive: • TDF: 38.3 • ETV: 33.3; P = 0.70 % HBV-DNA > 2000 IU/ml: • TDF: 21.7 • ETV: 35; P = 0.49 % HBV-DNA > 10^4 IU/ml: • TDF: 17.4 • ETV: 20; P = 1 Biochemical parameters (e.g., ALT, AST, bilirubin, albumin, creatinine, eGFR, phosphorus and platelet): No difference between groups (P > 0.05)	**Intervention:** TDF (n = 60); 245 mg/day **Comparator:** ETV (n = 60); 0.5 mg/day TDF and ETV were started simultaneous with the IST.	Outcomes: • HBV reactivation or hepatitis rates (HBV reactivation was defined as ≥ 1 log increase in HBV-DNA from baseline levels or reappearance of HBV-DNA in an individual who previously had an undetectable HBV-DNA) • Side effects Follow-up: 1 year after completion of IST.
Buti et al. (2017)[18] Spain	Multi-centre, phase IV, open-label, parallel	Anti-HBc-positive patients with hematological malignancy receiving RTX-based regimens either as	**Intervention** TDF (n = 33); 300 mg/day	Outcomes: • Rates of undetectable

Study citation, country, funding source	Study design	Population characteristics	Intervention and comparator(s)	Clinical outcomes, length of follow-up
Funding source: Gilead Sciences	RCT Settings: 17 hospitals Sample size calculation: Yes ITT analysis: Yes	monotherapy or as combination with chemotherapy. Mean age (SD), years: • TDF: 69.9 (13.3) • Obs: 71.4 (9.02); P = 0.97 % Male: • TDF: 55.2 • Obs: 64.3; P = 0.59 % Anti-HBc-positive: • TDF: 100 • Obs: 100; P = 1 % Anti-HBs-positive: • TDF: 62.1 • Obs: 75.0; P = 0.51 Mean RTX cycles (SD): • TDF: 5.38 (4.2) • Obs: 6.36 (3.07); P = 0.29 Malignancy (e.g., non-Hodgkin lymphoma, chronic lymphatic leukemia, nodular sclerosis Hodgkin lymphoma, nodal marginal lymphoma): No difference between groups (P = 0.31)	**Comparator:** Observation (n = 28)	HBV-DNA levels (reactivation defined as HBsAg and/or HBV-DNA detection, or a confirmed $\geq 1 \log_{10}$ IU/mL increase in HBV-DNA levels from baseline) • Liver and renal functional tests • Incidence of ALT flares (defined by > 5-fold ALT increase) Treatment duration: 18 months.
Inada et al. (2021)[19] Japan **Funding source:** Japan Agency for Medical Research and Development	Retrospective cohort study Sample size calculation: No Adjustment for confounders: No	Patients receiving TAF or ETV as prophylaxis against or treatment of HBV reactivation during chemotherapy or IST from January 2010 to June 2020. Median age (range), years: • TAF: 69 (52 to 81) • ETV: 68 (39 to 87); P = 0.86 % Male: • TAF: 63.6 • ETV: 51.5; P = 0.53 Median HBV-DNA (range), log IU/mL: • TAF: 2.3 (0 to 9.1) • ETV: 3.1 (0 to 8.3); P = 0.50 Median ALT (range), U/mL: • TAF: 17.0 (11 to 1,489) • ETV: 18.5 (7 to 1,363); P = 0.39 % HBeAg (+/ - / missing): • TAF: 18.2/72.7/9.0	**Intervention:** TAF (n = 11); dosage NR **Comparator:** ETV (n = 66); dosage NR	Outcomes: • HBV-DNA levels • Proportion of patients with undetectable HBV-DNA • eGFR levels Treatment duration: 24 weeks.

Study citation, country, funding source	Study design	Population characteristics	Intervention and comparator(s)	Clinical outcomes, length of follow-up
		• ETV: 13.6/66.7/19.7; P = 0.79 Median HBsAg (range), IU/mL: • TAF: 398.66 (0.005 to 113,000) • ETV: 280.00 (0.00 to 24,114.97); P = 1.0 Median eGFR (range), ml/min/1.73 m^2): • TAF: 70.9 (35.3 to 99.3) • ETV: 72.9 (4.1 to 129.5); P = 0.86 Median treatment duration (range), days: • TAF: 216 (128 to 567) • ETV: 1,120 (126 to 3,378); P < 0.001 % Original diseases (malignant lymphoma/other cancer/others: • TAF: 27.3/45.5/27.3 • ETV: 24.2/43.9/32; P = 1.0		

Lee et al. (2018)[20]
Taiwan
Funding source: Taipei General Hospital; Ministry of Science and Technology
	Retrospective cohort study
	Sample size calculation: No
	Adjustment for confounders: No
		Patients receiving TDF or ETV as antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy
		Mean age (SD), years:
		• TDF: 57.4 (12.0)
		• ETV: 58.3 (12.1); P = 0.48
		% Male:
		• TDF: 47.2
		• ETV: 46.9; P = 1.00
		Mean total chemotherapy duration (SD), months:
		• TDF: 5.1 (3.1)
		• ETV: 6.0 (4.7); P = 0.19
		Mean HBV-DNA (SD), log IU/mL:
		• TDF: 2.88 (1.67)
		• ETV: 3.14 (1.82); P = 0.30
		% HBV-DNA < 2,000 IU/mL:
		• TDF: 63.2
		• ETV: 62.5; P = 0.67
		% HBsAg (+):
		• TDF: 2.8
		• ETV: 5.3; P = 0.50
		Baseline biochemistry parameters
			Intervention:
			TDF (n = 106); 300 mg/day
			Comparator:
			ETV (n = 113); 0.5 mg/day
				Outcomes:
				• Side effects (Nephrotoxicity)
				  ○ eGFR levels
				  ○ Incidence of renal events
				  ○ Acute kidney injury
				• Virology response rate (defined as achieving undetectable HBV DNA after nucleoside and nucleotide therapy)
				• HBV reactivation (defined as an increase in HBV DNA levels 10-fold or more compared with the previous nadir levels)
				Median treatment duration: 14 months

Study citation, country, funding source	Study design	Population characteristics	Intervention and comparator(s)	Clinical outcomes, length of follow-up
		(e.g., ALT, AST, Albumin, total bilirubin, BUN, creatinine, eGFR): No difference between groups (P > 0.05)		

ALT = alanine transaminase; Anti-HBc = hepatitis B core antibody; AST = aspartate aminotransferase; BUN = blood urea nitrogen; DNA = deoxyribose nucleic acid; ETV = entecavir; eGFR = estimated glomerular filtration rate; HBeAg = hepatitis B envelop antigen; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; IST = immunosuppressive therapy; ITT = intention-to-treat; IU = international unit; NR = not reported; Obs = observation; NR = not reported; RCT = randomized controlled trial; RTX = rituximab; SD = standard deviation; TAF = tenofovir alafenamide fumarate; TDF = tenofovir disoproxil fumarate.

Table 3: Characteristics of Included Guidelines

Intended users, target population	Intervention and practice considered	Major outcomes considered	Evidence collection, selection, and synthesis	Evidence quality assessment	Recommendations development and evaluation	Guideline validation
GESA, Lubel et al. (2022)[21]						
Intended users: Health professionals involved in the care of patients living with hepatitis B infection **Target population**: Patients with hepatitis B infection including people with viral coinfection, immunosuppressed individuals, those with renal impairment and pregnant women, especially with regard to preventing vertical transmission.	Evaluation, treatment (antiviral therapy) and management of patients with hepatitis B infection.	All outcomes related to the intervention and practice considered.	Evidence collection, selection and synthesis were not reported. Recommendations were made by consensus.	Quality of evidence and strength of recommendation were graded using the GRADE system. Quality of evidence: high (A), moderate (B), low (C), very low (D) Strength of recommendation: strong (1) or weak (2)	The consensus statements were developed using the principles outlined by the AGREE II instrument. The modified Delphi approach was used to determine the consensus. Sixty-eight experts in HBV infection management, and patient representatives were invited to participate the modified Delphi process.	The guideline was published in a peer-reviewed journal.
AGIHO, Christopeit et al. (2021)[22]						
Intended users: Physicians involving the care of patients with hematologic malignancies **Target population**: Patients with hematologic malignancies receiving HDC and ASCT.	Prophylaxis, diagnosis and treatment of infectious complications after HDC/ASCT.	All outcomes related to the intervention and practice considered.	Evidence collection, selection and synthesis were not reported. Recommendations were made by consensus.	Quality of evidence[a] and strength of recommendation[b] were graded using the defined criteria.	The expert panel assessed the recommendations in a stepwise consensus process.	The guideline was approved by AGIHO and was published in a peer-reviewed journal.
SBH and SBI, Ferraz et al. (2020)[23]						
Intended Users: Health professionals involved in the care of patients with HBV infection	Diagnosis and treatment of hepatitis B.	All outcomes related to the intervention	Evidence collection, selection and synthesis were not reported.	Quality of evidence[c] and strength of recommendation[d] were graded using the GRADE	The recommendations were developed by a panel of experts from SBH and SBI based on evidence from the	The guideline was published in a peer--

Intended users, target population	Intervention and practice considered	Major outcomes considered	Evidence collection, selection, and synthesis	Evidence quality assessment	Recommendations development and evaluation	Guideline validation
Target Population: Individuals infected with HBV.		and practice considered.		system. Quality of evidence: I, RCT; II-1, controlled trials without randomization; II-2, cohort or case-control analytical studies; II-3,	literature and on the experts' experience.	reviewed journal.
centered: Doyle et al. (2019)[24]
Intended users: Health professionals involved in the care of patients undergoing cancer therapy and patients with chronic HBV infection. **Target population**: Patients undergoing therapy for hematological and solid tumour malignancies.	Testing and management of HBV in patients undergoing therapy for hematological and solid tumour malignancies.	All outcomes related to the intervention and practice considered.	Recommendations were developed through a review of existing guidelines and published literature.	Quality of evidence and strength of recommendation were graded using the GRADE system. Quality of evidence: high (A), moderate (B), low (C) Strength of recommendation: strong (1) or weak (2)	This consensus statement was developed by medical specialists with expertise in infectious diseases, hepatology, hematology, oncology and pediatrics, and representatives from various societies,	The guideline was reviewed externally and published in a peer-reviewed journal.
centered: INASL, Arora et al. (2018)[25]
Intended users: Health professionals involved in the care of patients with HBV infection receiving chemotherapy, biologicals, immunosuppressants or corticosteroids. **Target population**: Patients with HBV infection receiving chemotherapy, biologicals,	Addressing issues on management of HBV infection in patients receiving chemotherapy, biologicals, immuno-suppressants, or steroids.	All outcomes related to the intervention and practice considered.	Evidence collection, selection and synthesis were not reported. Recommendations were made by consensus.	Quality of evidence and strength of recommendation were graded using the GRADE system. Quality of evidence: high (A), moderate (B), low (C), very low (D) Strength of	The taskforce first identified contentious issues on the topic of HBV reactivation in patients receiving chemotherapy, biologicals, immunosuppressants, or steroids. The consensus statements were discussed, debated and finalized in a one-day round table meeting.	The guideline was published in a peer-reviewed journal.

CADTH Health Technology Review Antiviral Prophylaxis With Tenofovir for Patients With History of Hepatitis B Receiving Oncology Drug Treatment

24

Intended users, target population	Intervention and practice considered	Major outcomes considered	Evidence collection, selection, and synthesis	Evidence quality assessment	Recommendations development and evaluation	Guideline validation
immunosuppressants or corticosteroids.				recommendation: strong (1) or weak (2)		
ASCO and IDSA, Taplitz et al. (2018)[26]						
Intended users: Health professionals involved in the care of adult patients undergoing cytotoxic immunotherapy and stem-cell transplantation. **Target population**: Patients with immunosuppression associated with cancer and its treatment.	Antimicrobial prophylaxis for adult patients with immunosuppression associated with cancer and its treatment.	All outcomes including cost implications related to the intervention and practice considered.	A systematic review was conducted to search for relevant literature.	Quality of evidence[e] and strength of recommendation[f] were graded using the defined criteria.	The guideline employs the ASCO Guidelines Methodology Manual[30] to develop and evaluate the recommendations.	The guideline was reviewed internally, externally and published in a peer-reviewed journal.
CASL and AMMIDC (2018)[27]						
Intended users: Health professionals involved in the care of patients with HBV infection **Target population**: Patients with HBV infection.	Management of HBV infection.	All outcomes related to the intervention and practice considered.	Evidence collection, selection and synthesis were not reported. Recommendations were made by consensus.	Quality of evidence[g], and class of evidence[h] were graded using the GRADE system.	The CASL appointed an organizing Committee, which invited experts to review the current literature on various topics. The experts made presentations and addressed questions from the audience. A writing committee assessed the information from the presentations and from other sources and prepared a document that was circulated for comment.	The guideline was published in a peer-reviewed journal.
SIMIT, SIE, GITMO, and SIVIM, Sarmati et al. (2017)[28]						
Intended users: Health professionals involved in the	Screening, monitoring, prevention,	All outcomes related to the	A systematic review was conducted to	The results of the systematic review	The position paper was developed from 1 meeting	The guideline was published

CADTH Health Technology Review Antiviral Prophylaxis With Tenofovir for Patients With History of Hepatitis B Receiving Oncology Drug Treatment

25

Intended users, target population	Intervention and practice considered	Major outcomes considered	Evidence collection, selection, and synthesis	Evidence quality assessment	Recommendations development and evaluation	Guideline validation
care of patients with HBV infection with hematologic malignancies and patients who underwent hematologic stem cell transplantation. **Target population**: Patients with hematologic malignancies and patients who underwent hematologic stem cell transplantation.	prophylaxis, and therapy of HBV reactivation in patients with hematologic malignancies and patients who underwent hematologic stem cell transplantation.	intervention and practice considered.	search for relevant literature.	were evaluated by GRADE methodology to provide a systematic method of grading both the strength of recommendation (weak or strong) and the quality of evidence (very low, low, moderate, and high).	held in Rome in July 2015 that involved a team of experts from the SIMIT, SIE, GITMO, and SIVIM.	in a peer-reviewed journal.

AGIHO = Infectious Diseases Working Party; AGREE II = Appraisal of Guidelines for Research and Evaluation II; AMMIDC = Association of Medical Microbiology and Infectious Disease Canada; ASCO = American Society of Clinical Oncology; ASCT = autologous stem cell transplantation; CASL = Canadian Association for the Study of the Liver; GESA = Gastroenterological Society of Australia; GRADE = Grading of Recommendations Assessment, Development and Evaluation; GITMO = Italian Group of Bone Marrow Transplantation; HBV = hepatitis B virus; HDC = high-dose chemotherapy; INASL = Indian National Association for Study of the Liver; RCT = randomized controlled trial; SBH = Brazilian Society of Hepatology; SBI = Brazilian Society of Infectious Diseases; SIE = Italian Society of Hematology; SIMIT = Italian Society of Infectious Diseases; SIVIM = Italian Society of Virology.

[a]Quality of evidence: **I**: Evidence from at least 1 properly designed randomized, controlled trial. **II**: Evidence from at least 1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from > 1 centre); from multiple time series; or from dramatic results of uncontrolled experiments; **IIr**: meta-analysis or systematic review of RCT; **IIt**: transferred evidence, i.e., results from different patient cohorts or similar immune status situation; **IIh**: comparator group historical control; **IIu**: uncontrolled trials; **IIa**: published abstract, presented at an international symposium or meeting. **III**: Evidence from opinions of respected authorities, based on clinical experience, descriptive case studies

[b]Strength of recommendation: **A**: AGIHO strongly supports a recommendation for use; **B**: AGIHO moderately supports a recommendation for use; **C**: AGIHO marginally supports a recommendation for use; **D**: AGIHO supports a recommendation against use.

[c]Quality of evidence: **I**: RCT; **II-1**: controlled trials without randomization; **II-2**: cohort or case-control analytical studies; **II-3**: Multiple time series, dramatic uncontrolled experiments; **III**: Opinions of respected authorities, descriptive epidemiology

[d]Strength of recommendation: **1: Strong**: Factors influencing the strength of the recommendation included quality of the evidence, presumed patient-important outcomes, and cost; **2: Weaker**: Variability in preferences and values, or more uncertainty: more likely a weak recommendation is warranted. Recommendation is made with less certainty: higher cost or resource consumption.

[e]Quality of evidence: **High**: High confidence that the available evidence reflects the true magnitude and direction of the net effect (e.g., balance of benefits vs. harms) and further research is very unlikely to change either the magnitude or direction of this net effect. **Intermediate**: Intermediate confidence that the available evidence reflects the true magnitude and direction of the net effect. Further research is unlikely to alter the direction of the net effect, however it might alter the magnitude of the net effect. **Low**: Low confidence that the available evidence reflects the true magnitude and direction of the net effect. Further research may change the magnitude and/or direction of this net effect. **Insufficient**: Evidence is insufficient to discern the true magnitude and direction of the net effect. Further research may better inform the topic. Reliance on consensus opinion of experts may be reasonable to provide guidance on the topic until better evidence is available.

[f]Strength of recommendation: **Strong:** There is high confidence that the recommendation reflects best practice. This is based on: a) strong evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, with no or minor exceptions; c) minor or no concerns about study quality; and/or d) the extent of panelists' agreement. Other compelling considerations (discussed in the guideline's literature review and analyses) may also warrant a strong recommendation. **Moderate:** There is moderate confidence that the recommendation reflects best practice. This is based on: a) good evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, with minor and/or few exceptions; c) minor and/or few concerns about study quality; and/or d) the extent of panelists' agreement. Other compelling considerations (discussed in the guideline's literature review and analyses) may also warrant a moderate recommendation. **Weak:** There is some confidence that the recommendation offers the best current guidance for practice. This is based on: a) limited evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, but with important exceptions; c) concerns about study quality; and/or d) the extent of panelists' agreement. Other considerations (discussed in the guideline's literature review and analyses) may also warrant a weak recommendation.

[g]Quality of evidence: **Level A:** High-quality evidence from multiple randomized clinical trials or meta-analyses. **Level B:** Data from a single randomized trial, or non-randomized studies. **Level C:** Further information might have an

impact on our confidence of the practice. **Level D:** Consensus opinion of experts, or case studies. Further information is needed to support the practice.

ʰClass of evidence: **Class 1:** Strong recommendation. There is high-quality evidence that supports the usefulness or efficacy of a given diagnostic test or treatment. **Class 2:** On the balance of evidence and opinion, there is support in favour of the usefulness or efficacy of a given diagnostic test or treatment. **Class 2a:** On the balance of evidence and opinion, there is support in favour of the usefulness or efficacy of a given diagnostic test or treatment. **Class 2b:** Usefulness/efficacy is less well established by evidence/opinion. **Class 3:** Cannot be recommended. Conditions for which there is evidence and/or general agreement that a diagnostic evaluation, procedure or treatment is not useful or effective and, in some cases, may be harmful.

Appendix 3: Critical Appraisal of Included Publications

Note that this appendix has not been copy-edited.

Table 4: Strengths and Limitations of Clinical Studies Using the Downs and Black Checklist[14]

Strengths	Limitations
RCTs	
Toka et al. (2021)[17]	
Reporting: • The objective of the study, the main outcomes to be measured, the characteristics of the patients included in the study, the interventions of interest, and the main findings were clearly described. • Adverse events of the intervention were reported. • There were no group differences in demographics of the randomized patients. • Actual probability and standard deviation values were reported for the main outcomes. **Internal validity – bias:** • All patients were followed up for 1 year after prophylaxis treatment. • Statistical tests were used appropriately, and the main outcome measures were accurate and reliable. • The main outcome measures used were accurate. **Internal validity – confounding:** • Patients in different interventions groups were recruited from the same population and over the same period. • Sample size calculation was performed. The study had sufficient power to detect a clinically important effect.	**Reporting:** • The characteristics of patients lost to follow-up were not described. 35% death due to primary disease during prophylaxis. **External validity:** • Patients were recruited from 1 centre. It was unclear if the patients represent the entire population from which they were recruited. • Patients were treated at a university setting. It was unclear if the staff, place, and facility where the patients were treated, were representative of the treatment the majority of the patients receive. **Internal validity – bias:** • This was an RCT, but the blinding status was not reported. Non-blinding of patients and personnel may lead to performance bias, and non-blinding of outcome assessors may result in detection bias. **Internal validity – confounding:** • Method of allocation concealment was not reported. • The ITT approach was not applied in the analyses.
Buti et al. (2017)[18]	
Reporting: • The objective of the study, the main outcomes to be measured, the characteristics of the patients included in the study, the interventions of interest, and the main findings were clearly described. • Adverse events of the intervention were reported. • There were no group differences in demographics of the randomized patients. • There were no patients lost to follow-up. **Internal validity – bias:** • All patients were followed up for 18 months. • Statistical tests were used appropriately, and the main outcome measures were accurate and reliable. • The main outcome measures used were accurate.	**Reporting:** • The characteristics of patients lost to follow-up were not described. **External validity:** • Although patients were recruited from 17 hospitals. It was unclear if the patients represent the entire population from which they were recruited. **Internal validity – bias:** • This was an open-label RCT. Non-blinding of patients and personnel may lead to performance bias, and non-blinding of outcome assessors may result in detection bias. **Internal validity – confounding:** • Method of allocation concealment was not reported. • Sample size calculation was performed, but the calculated

Strengths	Limitations
External validity: • Patients were treated at the hospital settings. It was likely that the staff, places, and facilities where the patients were treated, were representative of what most patients receive during treatment. **Internal validity − confounding:** • Patients in different interventions groups were recruited from the same population and over the same period of time. • The analyses were conducted using the ITT approach.	sample size was not reached. It is unclear if the study had sufficient power to detect a clinically important effect.
Non-randomized studies	
Inada et al. (2021)[19]	
Reporting: • The objective of the study, the main outcomes to be measured, the characteristics of the patients included in the study, the interventions of interest, and the main findings were clearly described. • There were no apparent group differences in most reported demographics of the included patients, except treatment duration. • Adverse events of the intervention were reported. • Actual probability and standard deviation values were reported for the main outcomes. **External validity:** • The clinical records were collected from a hospital. The staff, places, and facilities where the patients were treated, might be representative of what most patients receive during treatment. **Internal validity − bias:** • Statistical tests were used appropriately, and the main outcome measures were accurate and reliable. **Internal validity − confounding:** • It was likely that patients in both intervention groups were recruited from the same population and over the same period (Patients were from 1 hospital receiving antiviral prophylaxis for HBV reactivation between January 2010 to June 2020).	**External validity:** • It was unclear if the selected patients represented the entire population from which they were treated. **Internal validity − bias:** • This was a non-randomized study, which was prone to high risk of bias for selection and performance. **Internal validity − confounding:** • Confounding variables were not identified and adjusted for in the analyses. This may have significant impact to the findings. • The authors of the study did not provide a sample size calculation. Therefore, it was unclear if the study was sufficiently powered to detect statistically significant difference in effect between groups for all outcomes.
Lee et al. (2018)[20]	
Reporting: • The objective of the study, the main outcomes to be measured, the characteristics of the patients included in the study, the interventions of interest, and the main findings were clearly described. • There were no apparent group differences in most reported demographics of the included patients. • Adverse events of the intervention were reported.	**External validity:** • It was unclear if the selected patients represented the entire population from which they were treated. **Internal validity − bias:** • This was a non-randomized study, which was prone to high risk of bias for selection and performance. **Internal validity − confounding:** • Confounding variables were not identified and adjusted for

Strengths	Limitations
• Actual probability and standard deviation values were reported for the main outcomes. **External validity:** • The clinical records were collected from a hospital. The staff, places, and facilities where the patients were treated, might be representative of what most patients receive during treatment. **Internal validity – confounding:** • It was likely that patients in both intervention groups were recruited from the same population and over the same period (Patients were from 1 hospital receiving antiviral prophylaxis for HBV reactivation between June 2015 to April 2016).	in the analyses. This may have significant impact to the findings. • The authors of the study did not provide a sample size calculation. Therefore, it was unclear if the study was sufficiently powered to detect statistically significant difference in effect between groups for all outcomes.

HBV = hepatitis B virus; ITT = intention-to-treat; RCT = randomized controlled trial.

Table 5: Strengths and Limitations of Guidelines Using AGREE II[15]

Item	GESA, Lubel et al. (2022)[21]	AGIHO, Christopeit et al. (2021)[22]	SBH and SBI, Ferraz et al. (2020)[23]	Doyle et al. (2019)[24]	INASL, Arora et al. (2018)[25]	ASCO and IDSA, Taplitz et al. (2018)[26]	CASL and AMMIDC (2018)[27]	SIMIT, SIE, GITMO, and SIVIM, Sarmati et al. (2017)[28]
Domain 1: scope and purpose								
1. The overall objective(s) of the guideline is (are) specifically described.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
2. The health question(s) covered by the guideline is (are) specifically described.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Domain 2: stakeholder involvement								
4. The guideline development group includes individuals from all relevant professional groups.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
5. The views and preferences of the target population (patients, public, etc.) have been sought.	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
6. The target users of the guideline are clearly defined.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Domain 3: rigour of development								
7. Systematic methods were used to search for evidence.	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
8. The criteria for selecting the evidence are clearly described.	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
9. The strengths and limitations of the body of evidence are clearly described.	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear

Item	GESA, Lubel et al. (2022)[21]	AGIHO, Christopeit et al. (2021)[22]	SBH and SBI, Ferraz et al. (2020)[23]	Doyle et al. (2019)[24]	INASL, Arora et al. (2018)[25]	ASCO and IDSA, Taplitz et al. (2018)[26]	CASL and AMMIDC (2018)[27]	SIMIT, SIE, GITMO, and SIVIM, Sarmati et al. (2017)[28]
10. The methods for formulating the recommendations are clearly described.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
11. The health benefits, side effects, and risks have been considered in formulating the recommendations.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
12. There is an explicit link between the recommendations and the supporting evidence.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
13. The guideline has been externally reviewed by experts before its publication.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
14. A procedure for updating the guideline is provided.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Domain 4: clarity of presentation								
15. The recommendations are specific and unambiguous.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
#16.3 The different options for management of the condition or health issue are clearly presented.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
17. Key recommendations are easily identifiable.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Domain 5: applicability								
18. The guideline describes facilitators and barriers to its application.	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
19. The guideline provides advice and/or tools on how the recommendations can be put into practice.	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear

Item	GESA, Lubel et al. (2022)[21]	AGIHO, Christopeit et al. (2021)[22]	SBH and SBI, Ferraz et al. (2020)[23]	Doyle et al. (2019)[24]	INASL, Arora et al. (2018)[25]	ASCO and IDSA, Taplitz et al. (2018)[26]	CASL and AMMIDC (2018)[27]	SIMIT, SIE, GITMO, and SIVIM, Sarmati et al. (2017)[28]
20. The potential resource implications of applying the recommendations have been considered.	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
21. The guideline presents monitoring and/or auditing criteria.	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Domain 6: editorial independence								
22. The views of the funding body have not influenced the content of the guideline.	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
23. Competing interests of guideline development group members have been recorded and addressed.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

AGIHO = Infectious Diseases Working Party; AGREE II = Appraisal of Guidelines for Research and Evaluation II; AMMIDC = Association of Medical Microbiology and Infectious Disease Canada; ASCO = American Society of Clinical Oncology; ASCT = autologous stem cell transplantation; CASL = Canadian Association for the Study of the Liver; GESA = Gastroenterological Society of Australia; GRADE = Grading of Recommendations Assessment, Development and Evaluation; GITMO = Italian Group of Bone Marrow Transplantation; HBV = hepatitis B virus; HDC = high-dose chemotherapy; INASL = Indian National Association for Study of the Liver; RCT = randomized controlled trial; SBH = Brazilian Society of Hepatology; SBI = Brazilian Society of Infectious Diseases; SIE = Italian Society of Hematology; SIMIT = Italian Society of Infectious Diseases; SIVIM = Italian Society of Virology.

Appendix 4: Main Study Findings

Note that this appendix has not been copy-edited.

Table 6: Summary of Findings by Outcome — HBV Reactivation

Author (year) and study design	Study findings
Toka et al. (2021)[17] RCT	**TDF (n = 60) vs. ETV (n = 60)** During the antiviral prophylaxis: • All patients became HBV-DNA negative within 12 months of starting antiviral prophylaxis. • Time to achieved DNA negativity: TDF, 5.22 ± 3.02 months vs. 5.40 ± 3.16 months; P = 0.84 • No HBV reactivation was observed. During follow-up after completion of the antiviral prophylaxis: • 14.3% (5 of 35) in the TDF group vs. 10.8% (4 of 37) in ETV group had HBV reactivation, P = NR
Buti et al. (2017)[18] RCT	**TDF (n = 33) vs. Observation (n = 28)** During the antiviral prophylaxis: • ITT: 0% (0/33) in the TDF group vs. 10.7% (3/28) in the observational group; P = 0.091. • PP: 0% (0/30) in the TDF group vs. 12.5% (3/24) in the observational group; P = 0.082.
Inada et al. (2021)[19] Retrospective cohort study	**TAF (n = 11) vs. ETV (n = 66)** Antiviral efficacy (decrease of serum HBV-DNA): • From week 0 to week 24: −3.04 ± 2.47 vs. −2.83 ± 1.45; P = 0.857 • At week 24: HBV-DNA was undetectable in serum of the patients in TAF group (90.9%) and in ETV group (78.8%); P = 0.681
Lee et al. (2018)[20] Retrospective cohort study	**TDF (n = 106) vs. ETV (n = 113)** • HBV reactivation rates: 0.9% (1 patient) vs. 0.9% (1 patient); P = 1.00 • Virological response rates: 95.5% vs. 85.7%; P = 0.056

DNA = deoxyribose nucleic acid; ETV = entecavir; HBV = hepatitis B virus; RCT = randomized controlled trial; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; vs. = versus.

Table 7: Summary of Findings by Outcome — Side Effects

Author (year) and study design	Study findings
	Kidney function

Buti et al. (2017)[18]
RCT
	Results for TDF (n = 33) and Observation (n = 28)
	• Serum creatinine, mean (range), mg/dL:
	    TDF: Baseline: 0.8 (0.4 to 1.2) vs. Month 18: 0.9 (0.6 to 1.3); P = 0.054
	    Observation: Baseline: 0.9 (0.5 to 1.2) vs. Month 18: 1.0 (0.5 to 1.4); P = 0.03
	• eGFR, mean (range), mL/min/1.73 m^2:
	    TDF: Baseline: 93.7 (62.2 to 205.1) vs. Month 18: 81.6 (57.4 to 111.8); P = 0.071
	    Observation: Baseline: 86.6 (61.3 to 136.5) vs. Month 18: 77.6 (40.2 to 149.6); P = 0.034
	• Creatinine clearance, mean (range):

Author (year) and study design	Study findings
	TDF: Baseline: 86.5 (51.2 to 286.4) vs. Month 18: 77.3 (38.4 to 145.6); P = 0.022
	Observation: Baseline: 81.0 (37.8 to 168.8) vs. Month 18: 75.5 (23.0 to 145.3); P = 0.016
	• Phosphate, mean (range), mg/dL:
	TDF: Baseline: 3.2 (1.2 to 4.4) vs. Month 18: 3.1 (2.2 to 4.1); P = 0.17
	Observation: Baseline: 3.2 (2.0 to 4.3) vs. Month 18: 3.3 (2.1 to 4.1); P = 0.541
Inada et al. (2021)[19] Retrospective cohort study	**TAF (n = 11) vs. ETV (n = 66)** eGFR, mean (SD), mL/min/1.73 m^2: TDF: Week 0: 72.2 (19.0) vs. Week 24: 68.6 (18.2); P = 0.185 ETV: Week 0: 70.7 (21.6) vs. Week 24: 70.1 (20.7); P = 0.865 Decrease in eGFR: −3.67 (13.19) in TDF group vs. −0.62 (11.22) in ETV group; P = 0.291
Lee et al. (2018)[20] Retrospective cohort study	**TDF (n = 106) vs. ETV (n = 113)** • Incidence of acute kidney injury during antiviral prophylaxis: 33% vs. 38.9%; P = 0.441 • Incidence of sustained kidney injury: 11.3% vs. 11.5%; P = 1.000 • Decrease in eGFR ≥ 20%: 59.4% vs. 60.2%; P = 1.000 • Decrease in eGFR ≥ 50%: 9.4% vs. 18.6%; P = 0.081 • eGFR < 60 mL/min: 27.4% vs. 38.9%; P = 0.094 • eGFR < 30 mL/min: 3.8% vs. 11.5%; P = 0.060 • Dose adjustment: 12.3% vs. 23.9%; P = 0.040 • Serum phosphorous < 2 mg/dL: 4.7% vs. 4.4%; P = 1.000
	Liver Function

Buti et al. (2017)[18]
 	
RCT
	Results of TDF (n = 33) and Observation (n = 28)
	• ALT, mean (range), IU/L:
	     TDF: Baseline: 22.7 (9 to 95) vs. Month 18: 27.9 (9 to 110); P = 0.34
	     Observation: Baseline: 20.6 (7 to 60) vs. Month 18: 22.2 (8 to 89); P = 0.84
	• AST, mean (range), IU/L:
	     TDF: Baseline: 27.0 (9 to 68) vs. Month 18: 28.3 (14 to 94); P = 0.52
	     Observation: Baseline: 19.9 (9 to 67) vs. Month 18: 19.7 (11 to 44); P = 0.27
	• GGT, mean (range), IU/L:
	     TDF: Baseline: 62.5 (6 to 611) vs. Month 18: 31.3 (8 to 77); P = 0.16
	     Observation: Baseline: 65.3 (11 to 496) vs. Month 18: 30.2 (10 to 87); P = 0.35
	• Bilirubin, mean (range), IU/L:
	     TDF: Baseline: 0.7 (0.32 to 2.3) vs. Month 18: 0.6 (0.2 to 1.3); P = 0.92
	     Observation: Baseline: 0.7 (0.2 to 1.4) vs. Month 18: 0.7 (0.7 to 1.8); P = 0.85
	• Albumin, mean (range), g/dL:
	     TDF: Baseline: 5.9 (2.2 to 4.9) vs. Month 18: 4.3 (3.6 to 4.8); P = 0.24
	     Observation: Baseline: 4.0 (2.9 to 4.8) vs. Month 18: 4.3 (3.7 to 4.8); P = 0.39
	• Alkaline phosphatase, mean (range), IU/L:
	     TDF: Baseline: 110 (32 to 360) vs. Month 18: 95.5 (72 to 362); P = 0.24

Author (year) and study design	Study findings
	Observation: Baseline: 90.3 (49 to 234) vs. Month 18: 90.9 (40 to 191); P = 0.32
	• Platelets/mm^3, mean (range):
	TDF: Baseline: 194,670 (5,100 to 568,000) vs. Month 18: 184,419 (49,500 to 337,000); P = 0.66
	Observation: Baseline: 203,096 (21,000 to 367,000) vs. Month 18: 189,578 (64,000 to 1274,000); P = 0.08
Others	
Toka et al. (2021)[17] RCT	**TDF (n = 60) vs. ETV (n = 60)** • Patients with at least 1 side effects: 23.3% vs. 16.7%; P = 0.77 • Side effects that did not require treatment disruption: sleep disturbances (6.7% vs. 5.0%), headache (6.7% vs. 5.0%), hematuria (0% vs. 3.3%), abdominal pain (3.3% vs. 1.7%), myalgia (1.7% vs. 1.7%), nausea (1.7% vs. 1.7%), weakness (5.0% vs. 5.0%), itching, rash on the skin (3.3% vs. 0%). • Side effects requiring treatment disruption: 1.7% vs. 0%.

ALT = alanine aminotransferase; AST = aspartate aminotransferase; ETV = entecavir; eGFR = estimated glomerular filtration rate; GGT = gamma-glutaryl transferase; RCT = randomized controlled trial; SD = standard deviation; TAF = tenofovir alafenamide fumarate; TDF = tenofovir disoproxil fumarate; vs. = versus.

Table 8: Summary of Recommendations in Included Guidelines

Recommendations and supporting evidence	Quality of evidence and strength of recommendations
GESA, Lubel et al. (2022)[21]	
"HBsAg positive people receiving cancer chemotherapy or moderate or high risk immunosuppression for non-malignant conditions should be treated with entecavir or tenofovir"[21] (p. 479) Evidence supporting this recommendation was from a previous guideline.	Quality of evidence: Moderate (B) Strength of recommendation: Strong (1)
"HBsAg negative/anti-HBc positive people who are being treated with agents associated with high risk of HBV reactivation should be treated with entecavir or tenofovir" [21] (p. 479) Evidence supporting this recommendation was from a previous guideline.	Quality of evidence: Moderate (B) Strength of recommendation: Strong (1)
AGIHO, Christopeit et al. (2021)[22]	
"AGIHO strongly recommends the use of either tenofovir or entecavir in patients with HBsAg- and/or anti-HBc positivity. Patients should regularly be monitored for reactivation despite antiviral prophylaxis by HBV DNA measurements. In addition to patients after HDC/ASCT, patients under steroid medication and patients after the use of anti-CD20-antibodies, e.g., during maintenance therapy after HDC/ASCT, are at high risk for HBV reactivation."[22] (p. 327) Evidence supporting this recommendation was from 2 RCTs	Quality of evidence: Transfer evidence (IIt) Strength of recommendation: Strong (A)
SBH and SBI, Ferraz et al. (2020)[23]	
"All candidates for chemotherapy or immunosuppressive therapy should undergo serological testing for hepatitis B (mandatory HBsAg and anti-HBc)"[23] (p. 441)	Quality of evidence: Level I Strength of recommendation: Strong (1)

Recommendations and supporting evidence	Quality of evidence and strength of recommendations
"Prophylaxis of reactivation should be performed based on the risk stratification shown in the attached table"[23] (p. 441)	Quality of evidence: Level II-2 Strength of recommendation: Strong (1)
"Entecavir or tenofovir should be used for prophylaxis and should be maintained for 6 months (12–18 months in the case of rituximab) after discontinuation of the immunosuppressive or immunobiological agent"[23] (p. 441)	Quality of evidence: Level II-2 Strength of recommendation: Strong (1)
Evidence supporting the above 3 recommendations was from 1 guideline, 1 systematic review with network meta-analysis, 3 narrative reviews, and 1 retrospective study.	—
Doyle et al. (2019)[24]	
"We recommend that all HBsAg positive patients with haematological or solid tumour malignancy undergoing therapy should receive antiviral prophylaxis"[24] (p. 464)	Quality of evidence: High (A) Strength of recommendation: Strong (1)
"Patients undergoing higher risk cancer therapy (haematopoietic stem cell transplantation; B cell-depleting, B cell active or anti-CD20 agents; acute leukaemia and high-grade lymphoma therapy) should receive antiviral prophylaxis"[24] (p. 464)	Quality of evidence: Moderate (B) Strength of recommendation: Strong (1)
"We recommend that antiviral prophylaxis should be commenced as soon as possible relative to the commencement of cancer therapy, but should not delay cancer therapy"[24] (p. 464)	Quality of evidence: Moderate (B) Strength of recommendation: Strong (1)
"We recommend the use of potent, high barrier to resistance nucleoside or nucleotide analogues (i.e., entecavir or tenofovir) for antiviral prophylaxis"[24] (p. 464)	Quality of evidence: High (A) Strength of recommendation: Strong (1)
"We recommend that antiviral prophylaxis for children should follow the same approach as for adults"[24] (p. 464)	Quality of evidence: Low (C) Strength of recommendation: Strong (1)
Evidence supporting all the above recommendations was from 2 meta-analyses, 4 RCTs, and 3 retrospective studies.	—
INASL, Arora et al. (2018)[25]	
"Pre-emptive antiviral prophylaxis with ETV, TDF or TAF is recommended for patients when HBsAg or HBV DNA is positive."[25] (p. 412)	Quality of evidence: High (A) Strength of recommendation: Strong (1)
"Treatment should be continued for at least 12 months after discontinuation of chemotherapy or immunosuppressive therapy (18 months for rituximab-based regimens and HSCT)."[25] (p. 412)	Quality of evidence: Moderate (B) Strength of recommendation: Strong (1)
"Patients who have only isolated anti-HBc positivity should be monitored with HBsAg, ALT and HBV DNA testing every 3 months during therapy and up to 6 months after. • Pre-emptive antiviral therapy with ETV, TDF or TAF should be started immediately on detection of HBsAg or HBV DNA positivity. • Pre-emptive antiviral therapy in patients with isolated anti-HBc-positive (with HBsAg and HBV DNA negative) can be initiated in high-risk groups such as patients with lymphoma under a rituximab-containing regimen or those undergoing HSCT."[25] (p. 412)	Quality of evidence: Moderate (B) Strength of recommendation: Strong (1)

Recommendations and supporting evidence	Quality of evidence and strength of recommendations
"In children following drugs should be used for pre-emptive pro-phylaxis or therapy • ETV for children > 2 years of age • ETV or TDF for children > 12 years of age."[25] (p. 412)	Quality of evidence: Moderate (B) Strength of recommendation: Strong (1)
Evidence supporting all the above recommendations was from 4 case-controlled studies, 1 prospective study, 2 retrospective studies, and 1 narrative review.	—
ASCO and IDSA, Taplitz et al. (2018)[26]	
"Treatment with a nucleoside reverse transcription inhibitor (e.g., entecavir or tenofovir) is recommended for patients at high risk of hepatitis B virus reactivation."[26] (p. 3050) Evidence supporting this recommendation was from 1 meta-analysis and 1 RCT.	Quality of evidence: Intermediate Strength of recommendation: Moderate
CASL and AMMIDC (2018)[27]	
"HBsAg-positive patients are at high risk of reactivation and should undergo either monitoring or prophylactic NA therapy (especially with moderate to potent immunosuppression)."[27] (p. 187)	Quality of evidence: Level A Class of evidence: 2 Strength of recommendation: Strong
"HBsAg-negative, anti-HBc-positive patients may be at risk of reactivation and, based on their degree of risk, should undergo either monitoring (if they have high anti-HBs titres of > 100−1,000 IU/L) or prophylactic NA therapy (especially if they are on B-cell-depleting therapies)."[27] (p. 187)	Quality of evidence: Level C Class of evidence: 2 Strength of recommendation: Moderate
"Potent NAs (ETV, TDF, or TAF) are preferred when prophylaxis is used; LAM is an alternative especially for HBsAg-negative, anti-HBc-positive cases."[27] (p. 187)	Quality of evidence: Level A Class of evidence: 2 Strength of recommendation: Strong
"After completion of IS therapy, monitoring or prophylaxis, as applicable, should continue for at least 12 months or until immune reconstitution, or longer in those who received B-cell-depleting therapies."[27] (p. 187)	Quality of evidence: Level B Class of evidence: 2 Strength of recommendation: Strong
Evidence supporting all the above recommendations was from 2 systematic reviews and meta-analyses, 1 RCT, and 2 prospective cohort studies.	—
SIMIT, SIE, GITMO, and SIVIM, Sarmati et al. (2017)[28]	
"The use of third-generation antiviral drugs (entecavir or tenofovir) is recommended in HBsAg-positive haematologic patients regardless of HBV DNA levels."[28] (p. 937) Evidence supporting this recommendation was from 2 RCTs and 2 retrospective studies.	Quality of evidence: Moderate Strength of recommendation: Strong
"Currently, entecavir and tenofovir, drugs with high genetic barriers to resistance, are preferred to lamivudine for the treatment of haematologic patients with chronic HBV infection regardless of their HBV DNA levels."[28] (p. 937) Evidence supporting this recommendation was from 4 narrative reviews.	Quality of evidence: entecavir: high; tenofovir: moderate Strength of recommendation: entecavir: strong; tenofovir: strong

Recommendations and supporting evidence	Quality of evidence and strength of recommendations
"Antiviral prophylaxis should be initiated at least 1 week before or in concomitance with starting chemotherapy. It should be continued for the duration of chemotherapy and should be administered for at least 12 to 24 months after chemotherapy withdrawal."[28] (p. 937) Evidence supporting this recommendation was from a retrospective study.	Quality of evidence: Moderate Strength of recommendation: Strong
"Subsequent monitoring for delayed HBV reactivation after the cessation of antiviral prophylaxis is essential (strong recommendation, high quality of evidence)."[28] (p. 937) Evidence supporting this recommendation was from an RCT.	Quality of evidence: High Strength of recommendation: Strong

AGIHO = Infectious Diseases Working Party; ALT = alanine transaminase; AMMIDC = Association of Medical Microbiology and Infectious Disease Canada; ASCO = American Society of Clinical Oncology; Anti-HBc = hepatitis B core antibody; ASCT = autologous stem cell transplantation; CASL = Canadian Association for the Study of the Liver; DNA = deoxyribose nucleic acid; ETV = entecavir; GESA = Gastroenterological Society of Australia; GITMO = Italian Group of Bone Marrow Transplantation; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HDC = high-dose chemotherapy; INASL = Indian National Association for Study of the Liver; HSCT = hematopoietic stem cell transplantation; LAM = lamivudine; NA = nucleos(t)ide analogue; RCT = randomized controlled trial; SBH = Brazilian Society of Hepatology; SBI = Brazilian Society of Infectious Diseases; SIE = Italian Society of Hematology; SIMIT = Italian Society of Infectious Diseases; SIVIM = Italian Society of Virology; TAF = tenofovir alafenamide fumarate; TDF = tenofovir disoproxil fumarate.

Appendix 5: References of Potential Interest

Guidelines and Recommendations with Unclear Methodology

1. Westin J, Aleman S, Castedal M, et al. Management of hepatitis B virus infection, updated Swedish guidelines. *Infect Dis.* 2020;52(1):1-22. PubMed

2. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis B virus infection: 2019 update. *Hepatol Res.* 2020;50(8):892-923. PubMed